Mark Pallen

Mark Pallen is a Professor of Microbial Genomics at Norwich Medical School, University of East Anglia. His work bridges genomics, microbiology, and public health, with a strong focus on bacterial taxonomy, nomenclature, and pathogen surveillance. He is actively contributing to global microbial systematics and infectious disease tracking through cutting-edge genomic methods.

Research Interests: His research spans microbial genomics, prokaryotic nomenclature, bacterial taxonomy, and the epidemiology of pathogens such as SARS-CoV-2 and Mycobacterium tuberculosis. He applies whole-genome sequencing and metagenomics to understand microbial diversity, evolution, and transmission dynamics. His work supports public health initiatives through wastewater surveillance, hospital microbiome studies, and antimicrobial resistance monitoring.

The recent publications highlight a consistent focus on bacterial systematics, genomic epidemiology, and standardization in microbial genomics. Themes include the refinement of nomenclature rules, reclassification of bacterial species, and development of bioinformatics pipelines. His work increasingly integrates One Health and open science principles.

Scientific Recognition:

• Active contributor to the International Code of Nomenclature of Prokaryotes
• ORCID: 0000-0003-1807-3657
• Referenced in 3 Wikipedia pages
• Research widely shared on social media (X/Twitter) and academic platforms

Collaborations and Advising: Mark Pallen collaborates extensively across international borders, particularly in Palestine, Israel, and Europe. His work involves interdisciplinary teams in genomics, epidemiology, and clinical microbiology. While no formal students are listed in the provided text, his collaborative publications suggest mentorship and leadership in research teams.

Labs and Research Teams: He is part of a dynamic research environment at Norwich Medical School, likely involved in genomic surveillance initiatives, microbial systematics projects, and public health collaborations. His team applies high-throughput sequencing and computational biology to address real-world health challenges.